This study investigates pancreatic cancer. It focuses on evaluating the effectiveness of an adjuvant chemotherapy regimen known as mFOLFIRINOX for patients in China.

This study evaluates how safe and effective this chemotherapy is for treating pancreatic cancer. It looks at patients' survival without the disease returning, overall survival, and quality of life.

• Who can participate: Adults aged 18 to 79 years with histologically confirmed adenocarcinoma of the pancreas that has been surgically removed may participate. Participants must have adequate organ function, no prior chemotherapy for cancer, and provide written informed consent.
• Study details: Participants will receive investigational chemotherapy after surgery to see how it affects their recovery and survival. The study will compare the chemotherapy's effects on disease-free survival, overall survival, and quality of life.
• Study timelines: The study will last 6 months.